French artificial heart manufacturer Carmat on Friday reported a strong year in 2024 with 42 implants of its Aeson artificial heart, anticipating continued strong momentum in 2025 with a doubling of sales.

The Group posted sales of 7 million euros in 2024, a 2.5-fold increase on fiscal 2023. Artificial heart implantation also increased by a factor of 2.5 over the period.

In a press release, the Group says it anticipates "significant growth in Aeson implantations in 2025" and therefore expects, "at the very least, a doubling of its sales in 2025 compared with 2024".

More than 90 patients have benefited from the Aeson artificial heart since the first implantation in 2013.

(Written by Mara Vîlcu, edited by Kate Entringer)